US 12,257,227 B2
Combination solution for treating chemotherapy refractory cancer
Chiang J. Li, Cambridge, MA (US)
Assigned to 1GLOBE BIOMEDICAL CO., LTD., Beijing (CN)
Appl. No. 17/284,654
Filed by 1GLOBE BIOMEDICAL CO., LTD., Beijing (CN)
PCT Filed Oct. 12, 2019, PCT No. PCT/CN2019/110904
§ 371(c)(1), (2) Date Apr. 12, 2021,
PCT Pub. No. WO2020/074010, PCT Pub. Date Apr. 16, 2020.
Claims priority of application No. 201811195239.3 (CN), filed on Oct. 12, 2018.
Prior Publication US 2021/0393571 A1, Dec. 23, 2021
Int. Cl. A61K 31/343 (2006.01); A61K 31/337 (2006.01); A61K 31/7068 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/343 (2013.01) [A61K 31/337 (2013.01); A61K 31/7068 (2013.01); A61P 35/00 (2018.01)] 21 Claims
 
1. A method for treatment of pancreatic cancer in a patient, said method comprising administering to said patient a combinatorial pharmaceutical composition, the combinatorial pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I):

OG Complex Work Unit Chemistry
or pharmaceutically acceptable salts and solvates thereof,
a low dose of gemcitabine or pharmaceutically acceptable salts and solvates thereof, and
a weekly dose of therapeutically effective amount of paclitaxel in an IV injectable formulation that is not nab-paclitaxel,
wherein, the therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts and solvates thereof is administered at a dose of about 80 mg to about 960 mg per day, the low dose of gemcitabine or pharmaceutically acceptable salts and solvates thereof is administered at a dose of about 100 mg/m2 to about 600 mg/m2 by infusion per week, the therapeutically effective amount of paclitaxel is administered at a dose of about 10 mg/m2 to about 80 mg/m2 by infusion per week, and
wherein the pancreatic cancer is refractory to conventional chemotherapy, at least one targeted cancer therapy, or both.